Subscribe via E-mail

Your email:

Medical Device CRO Blog

Current Articles |  RSS Feed

Should the FDA Modify the De Novo Process?

  
  
  

Senators Robert Casey and John McCain have introduced a bill to Congress titled the “Safe, Efficient, and Transparent Medical Device Approval Act” or ‘SET Device Act’. The goal of this bipartisan bill is to streamline the regulatory approval process for investigational devices by trimming down some regulations which the senators believe support innovation.

The act calls for Congress to amend the Federal Food, Drug, and Cosmetic (FD&C) Act with respect to medical device regulation, specifically in respect to the de novo process. The senators hope Congress will agree that the process should be changed so that new products can be evaluated directly without needing to determine whether there are similar devices on the market.

Under the current process companies must:

  • First, Submit a 510(k), even if no known predicate device exists
  • Then, the FDA will confirm there is no predicate device, and the product will receive a ‘Not Substantially Equivalent’ determination

As noted in the bill, the Institute of Medicine (IOM) released a report in July of 2011 which revealed “between 2005 and 2009, review times for novel therapeutic devices through the de novo process nearly tripled. The report concluded that the current de novo process has not met its potential as an alternative regulatory pathway, and recommended the establishment of a modified de novo process.”

In a news-release, Senator John McCain explained that “With the U.S. medical device industry struggling to maintain international leadership, this legislation streamlines the outdated regulatory approval process to improve patients’ access to safe and effective medical devices.” Overall, both senators are noted to agree that an updated process will help medical device companies across the country.

And, so far, the feedback from the medical device industry has been positive. In fact, the Advanced Medical Technology Association (AdvaMed) has expressed its strong support, praising the senators for introducing legislature aimed to modernize, and optimize the process.

What do you think of the bill? Do you agree this will help remove regulations that hurt the medical device industry? Share your thoughts with us!

Comments

I think, the medical process must be controlled with more efficiency. It would be important new distributed informal automatic databases for suppoortin dangerous processing with risk and with management patient risk. I have patented decision and project method S_T_A_R_S-Statistical Retrieval and Search of information to decision making, as Utility model 21532 Czech. I promised to take all leadership of new innovations and their implementation as strategic decision with minimum mistakes and risk to accept bad decision - with statistical sufficient accuracy and reliability! It is modern way to shorten time cca 5x for implementation each complicated innovation and with defined priorities. I sell my licence to worldwide my new conceptual vision to build efficiency strategic informal system S_T_A_R_S only with certification for each user only from licenced in cybernetic experienced organisations in whole world. Contact me forthwith!!!
Posted @ Wednesday, February 29, 2012 2:57 PM by Antonin Cuc
I absolutely support this proposed change to the De Novo process - at the moment it is so ambiguous and lacks transparency making it very hard as a regulatory professional to contribute effectively to project planning. Novel low risk devices are being released in other markets but cannot seem to navigate the De Novo process effectively. It will also help reduce 510(k) creep as manufacturers struggle to find SE with non similar devices and don't effectively demonstrate safety and efficacy of that device by avoiding the inherent differences between the products.
Posted @ Thursday, March 01, 2012 5:44 AM by Deirdre Barrow
The point is that the manufacturer innovations convince their customers - such as hospitals, that his new quality offer of medical equipments -allways must be carefully tested and best-designed and technically while observing the highest guarantee of efficiency and security for defined users - so as for their final clients - patients. Reliable name of manufacturer must offer guarantees each new user and a reliable supply of know-how for implementation new dangerous innovation perfectly, including the instructions and advice - how to organize the user's own work on workplaces with this new equipment purchased, how to verify and ensure proper sufficient training for its physicians and other staff of secondary using the product correctly, comprehensively. Already running in time for the user innovation must reduce usual time and costs - so much earlier and much better served the purpose and demonstrable improvement in the scientific management of patient risk management in every stage of development and stage of use of innovation, guarantee period and posquarantee services, enviromental liquidity. It must be ensured by linking the information with the manufacturer supplier and manufacturer of feedback information supervision over the whole sphere of the users. It must be obvious that a new generation of medical devices is the implementation of scientific management in all phases of life - ie, including a standard systematic monitoring and analysis of all adverse events and urgent measures for the projection of these experiences to the next cycles of activity of manufacturer. You buy for your firm and your country my licence to decision and projecting method S_T_A_R_S-Statistical Retrieval and Search of information to decision making. It is "4-dimensional description innovations problem to decision making with minimum risk with computer support"! 
Posted @ Thursday, March 01, 2012 6:47 AM by Antonín Cuc
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics